cbr 1

CBR-470-1 is a potent inhibitor of glycolytic phosphoglycerate kinase 1 (PGK1) that activates NRF2 by increasing methylglyoxal levels. CBR-470-1 is a non-covalent Nrf2 activator with neuroprotective activity that protects SH-SY5Y neuronal cells from MPP+-induced cytotoxicity by activating the Keap1-Nrf2 cascade. cytotoxicity induced by MPP+.

CBR Agonist-1 (27a-cis) is a cannabinoid receptor (CBR) agonist that targets CB1R with a Ki of 0.18 μM and CB2R with a Ki of 1.22 μM. It can be utilized to investigate diseases related to the endogenous cannabinoid system.

CBR-470-2, a glycine-substituted analog, activates NRF2 signaling, making it valuable for investigating glycolysis modulation in scientific research [1].

CBR-3465 is an inhibitor of mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase. The MIC of CBR-3465 against Mtb is 0.16 μM [1].

CBR-6672, a type II NADH dehydrogenase inhibitor, demonstrates potent antimycobacterial activity against mycobacterium tuberculosis (Mtb) with a minimum inhibitory concentration (MIC) of 0.14 μM [1].